News Scoop: Lumos Labs has FDA nod for ADHD DTx Prismira Lumos Labs has secured its first 510(k) clearance for a digital therapeutics offering, paving the way for entrance into the regulated app market.
News RWE study shows promise for digital treatment of adult ADHD A study of nearly 20,000 adults with self-reported ADHD diagnoses shows app-based games can improve scores on a battery of cognitive tests.
News Click, Boehringer DTx for schizophrenia passes phase 3 test Click and Boehringer Ingelheim make progress in software-enhanced drug treatment for schizophrenia with a positive phase 3 trial of their CT-155 app.
News App to support people with depression launches in GB A smartphone app for depression developed by Otsuka and Click Therapeutics has been launched in Great Britain, its first European market.
News Digital player Hinge Health rises sharply after NYSE debut In a signal of a return to investor appetite for digital health stocks, Hinge Health has raised an impressive $437 million in an IPO.
News Digital therapy for Tourette syndrome backed for NHS use A digital therapy to reduce the severity of chronic tic disorders like Tourette syndrome has been recommended for use by the NHS for the first time.
News Reaction to MSD's UK exit as government tries to renew talks The UK government is reported to be trying to restart talks over drug pricing and rebates after MSD's shock decision to scrap a £1bn investment spend.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face